Clinical Trial Update: Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL [Phase 2]

View source ↗

Summary

Phase 2 trial investigating penpulimab with R2-GemOx regimen for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Penpulimab
• R2-GemOx regimen

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type | Phase 2 | Status: UNKNOWN